2013年7月16日讯 /生物谷BIOON/ --雅培（Abbott）7月15日宣布，将支付5.6亿美元收购2家私人控股公司——Idev Technologies公司和OptiMedica公司，前者专注于冠状动脉植入物，后者专注于激光辅助眼科手术。这2笔收购，将有助于雅培扩充其医疗设备产品。
雅培称，将支付3.1亿美元的现金及债务收购总部位于美国得克萨斯州韦伯斯特市的Idev Technologies公司，该公司上市了一款支架（stent）Superva Veritas，这是一款自膨胀（self-expanding）网状管支架，已在欧洲上市，用于治疗四肢堵塞。该支架能够促进血液的流动，尤其是大腿和膝盖血管中的血液流动。在美国，该支架上市用于治疗癌症导致的胆管狭窄。
该笔交易预计将在今年年底完成，同时将不会影响雅培的年度指南。目前，雅培已经在销售一款最畅销的药物涂层支架Xience，用于冠状动脉疾病患者的治疗。
在另一项声明中，雅培宣布，将支付2.5亿美元现金收购位于美国硅谷的OptiMedica公司，该公司制造了一款计算机化的激光器（computerized laser），用于白内障手术。同时，雅培将支付高达1.5亿美元的里程碑款项，包括达到特定的销售目标及监管目标的里程碑款项。
OptiMedica公司的催化剂活性精密激光系统（Catalys Precision Laser System）代替了白内障手术过程中在更换晶状体（len）时所需的外科医生的手动操作步骤。
白内障手术包括移除浑浊的晶状体及植入人工晶状体。根据行业数据，2013年在全球范围内将开展近2200万例白内障手术。
Leerink Swann分析师Danielle Antalffy在一份报告中称，这2笔收购是“积极的战略（positive strategically）”，但她同时指出，雅培目前正面临着来自全球经济疲软的压力，尤其是在中国的营养品销售压力。（生物谷Bioon.com）
英文原文：Abbott Labs to pay $560M to acquire private companies focused on stents and laser eye surgery
July 15, 2013 - 11:48 am EDT WASHINGTON — Abbott Laboratories announced Monday it would pay a combined $560 million to acquire two privately-held companies focused on coronary implants and laser-assisted eye surgery.
The acquisitions of Idev Technologies and OptiMedica Corp will help the health care company expand its medical device offerings, a half-year after it spun off its main pharmaceutical offerings into a separate company. In January Abbott completed the spin-off of the drugmaker Abbvie, leaving it with a business model built around generic drugs, medical implants and nutritional formula. Abbvie markets company's branded prescription drugs, including the blockbuster Humira.
Abbott said Monday it will pay $310 million in cash and debt for Webster, Texas-based Idev Technologies, which markets a stent used to treat blockages in the limbs. The stent, called Superva Veritas, is a self-expanding mesh tube marketed in Europe to promote blood flow, particularly in vessels in the thigh and knee. In the U.S. the stent is marketed to treat narrowing of bile ducts caused by cancer.
The transaction is expected to close by the end of the year and will not impact the company's annual guidance. Abbott already sells the best-selling drug-coated stent, Xience, to treat patients with coronary artery disease.
In a separate announcement, Abbott said it would pay $250 million in cash for Silicon Valley-based OptiMedica Corp., which makes a computerized laser used in cataract surgery. Abbott will pay up to $150 million in milestone payments for reaching certain sales and regulatory goals.
OptiMedica's Catalys Precision Laser System replaces some of the manual steps required of surgeons when replacing the lens of the eye during cataract surgery.
Surgery for cataracts involves removing the clouded lens and replacing it with an artificial implant lens. Nearly 22 million cataract procedures will be performed globally in 2013, according to industry figures.
Leerink Swann analyst Danielle Antalffy said in a note that the acquisitions are "positive strategically." However, she noted that Abbott is being pressured by weakness in the global economy, particularly sales of nutritionals in China.
"We remain cautious on 2013 guidance," Antalffy said, reaffirming a "Market Perform" rating for the stock.
In midday trading, shares of North Chicago, Illinois-based Abbott fell 8 cents to $35.23.
